ClinicalTrials.gg
Not yet recruitingNCT06352268Updated Apr 8, 2024

Lesioning Procedures for Movement Disorders

An observational study in Dystonia, Parkinson Disease and Essential Tremor, sponsored by All India Institute of Medical Sciences, New Delhi. Not yet recruiting at 1 site in India. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by All India Institute of Medical Sciences, New Delhi · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Sex
All
01

Study summary

Dystonia is a rare syndrome with varying etiologies. Similarly, tremor conditions refractory to medical management and disabling that they need surgical interventions are rare in our setting. So far there are no randomized controlled trials of pallidotomy for management of dystonia. There is scant literature on the long term efficacy and safety of Pallidotomy, thalamotomy and other such lesioning procedures in the management of movement disorders. The current literature is significantly plagued by publication bias as case reports with successful outcomes are likely to be selectively published in journals or conference abstracts. Lesioning procedures though seem to be effective are often considered to be risky, especially bilateral pallidotomy is not preferred by several centres. However, our center routinely performs simultaneous bilateral pallidotomy. To generate long term data on the efficacy and safety of lesioning procedures in rare diseases like dystonias especially the effect of functional neurosurgery on varying etiologies of the disease, robust registries are required which collect data on all consecutive patients who undergo the procedure.

Read the detailed description

Introduction Deep brain stimulation surgery (DBS) has become the standard of care for the management of generalized dystonia and Parkinson's disease with motor fluctuations and disabling dyskinesias. It has been shown in Randomized controlled trials to be effective and safe. Since the last 30 years, DBS has been used to treat a variety of patients with dystonias, which are of varying etiologies. It has now become the standard of care for patients with Advanced Parkinson disease with motor fluctuations and dopaminergic drug induced dyskinesias. However, the DBS is an expensive system, needs hardware implantation and regular programming. It is associated with surgical implantation which may lead to complications such as infection of the hardware, leads and electrodes. Since it is expensive, it is out of reach for the majority of the patients who pay out of pocket. It leads to increased healthcare costs because of the initial expenses for the implant as well as regular follow ups for programming. The programming is currently labour intensive and needs long hours of observation with trial and error to find the optimum programming settings for the individual patient. This may need the patient to be admitted in the inpatient setting or multiple outpatient visits for the patient, which can lead to loss of working hours and burden on the healthcare system. Before the introduction of DBS by Benabid, functional neurosurgery with lesioning procedures such as pallidotomy, thalamotomy, subthalamotomy were used to manage movement disorders such as dystonia, tremors and Parkinson disease. However after the advent of DBS, these procedures have taken a backseat. Also there are no randomized trials for the safety and efficacy of lesioning procedures in dystonias. The current practice in various centers of the world is to unilateral pallidotomy in most cases of dystonia. Simultaneous bilateral pallidotomy is not preferred by several practitioners due to the risk of bulbar symptoms which may be irreversible in certain cases. However, our experience in our Institute suggests good outcomes in patients with various forms of focal and generalized dystonias undergoing simultaneous bilateral pallidotomy using radiofrequency ablation. Similarly the investigators have done pallidotomy for genetic dystonias such as NBIAs (Neuronal brain iron deposition), Wilson's disease who had disabling dystonias or medically refractory status dystonicus. However, the long term efficacy and safety of these patients is not clear as there are no registries or long term follow up data. Similarly in Parkinson Disease the investigators have only a handful of patients who underwent Pallidotomy. Systematic data collection in a multicentric registry to generate meaningful information for patients and clinicians help understand the risks and benefits of the procedures and offer relevant information for clinical decision making.

Problem statement Evidence based management requires robust data to make clinical decisions. This data is derived from studies which may be observational or interventional. In the evidence pyramid, meta-analysis of randomized controlled trials is considered to be of the highest quality of evidence. In some conditions due to the high effect size or due to the rarity of the disease, it may be difficult to conduct randomized controlled studies and the current practice is guided by available observational study literature. Dystonia is a rare syndrome with varying etiologies. Similarly, tremor conditions refractory to medical management and disabling that they need surgical interventions are rare in our setting. So far there are no randomized controlled trials of pallidotomy for management of dystonia. There is scant literature on the long term efficacy and safety of Pallidotomy, thalamotomy and other such lesioning procedures in the management of movement disorders. The current literature is significantly plagued by publication bias as case reports with successful outcomes are likely to be selectively published in journals or conference abstracts. Lesioning procedures though seem to be effective are often considered to be risky, especially bilateral pallidotomy is not preferred by several centres. However, our center routinely performs simultaneous bilateral pallidotomy. To generate long term data on the efficacy and safety of lesioning procedures in rare diseases like dystonias especially the effect of functional neurosurgery on varying etiologies of the disease, robust registries are needed which collect data on all consecutive patients who undergo the procedure. The screening log will include all patients who are being considered for lesioning procedures. How long after diagnosis or medical management the patients are referred for surgery is currently unknown. The patients often receive a course of medical management and botulinum toxin injections. However, the duration is variable. Likewise, even after surgical lesioning, the patients are often continued on medical treatment. The additive effects of surgery with supportive care, palliative care referral patterns, usage of other disease modifiying therapy in patients with wilson's disease etc. are currently not known and this cohort study will shed light on these parameters. Similarly it has been found that some of the patients develop recurrence of symptoms following pallidotomy - either due to progression of the disease or due to relapse as the different dystonia networks develop over time. In such cases some patients are evaluated with repeat imaging and may be subjected to second surgery. There is no data regarding re-do surgery, and these treatment trends will be captured in this cohort.

Review of literature Dystonia There are no randomized controlled trials (RCT) to study the efficacy and safety of pallidotomy or thalamotomy in the management of dystonia. The case series and case reports regarding pallidotomy in dystonia describe a heterogenous population of patients who had undergone the procedure. Most of the case series have a bias towards reporting favourable outcomes. The investigators found a meta-analysis of 100 patients who underwent bilateral procedures for dystonia. This meta-analysis described 33 studies with varying indications such as generalized dystonia, dystonic storm and focal dystonias. The majority of the patients had genetic causes of dystonia with DYT1 gene mutation being the most common known genetic cause. Some studies reported a staged bilateral procedures while some simultaneous bilateral pallidotomy. The median time of follow up was 12 months with a range of 2-180 months. This meta-analysis revealed that 8% patients had transient adverse effects while 11% had permanent adverse effects. The commonest adverse effects that were permanent involved bulbar dysfunction with dysarthria anarthria or mutism. Most of the patients had a lasting beneficial effect while 19% patients had relapse of symptoms on prolonged follow up. The time to relapse of symptoms ranged from 3 weeks to 4.5 years. The predictors of response or relapse were not apparent from this meta-analysis. Moreover, why pallidotomy was preferred in contrast to DBS is not clear from the reports. Another case series describing 89 patients who underwent radiofrequency pallidotomy suggested unacceptable rates of complications with bilateral pallidotomy such as medically refractory parkinsonism, dysarthria and dysphagia. However these are retrospective review of data and the adverse effects may have been selectively reported in both unilateral and bilateral cases. In our center 10 children underwent bilateral simultaneous pallidotomy over a 7 year period and it was found that two patients had undergone the procedure for medically refractory status dystonicus and both of them had resolution of the status dystonicus. Two patients with generalized dystonia had recurrence of symptoms over a follow up of 4.5 years while three had a sustained improvement of more than 40% improvement in BFMDRS (Burke Fahn Marsden Dystonia Rating scale).

Parkinson Disease Pallidotomy in Parkinson's disease has been performed since several decades even before the advent of medical management with levodopa was discovered. There are few RCTs which have looked at the effects of pallidotomy in patients with Parkinson Disease. The European academy of Neurology also recommends pallidotomy in the management of Parkinson's disease with motor fluctuations with dyskinesias being the most responsive symptom to therapy. However with the advent of Deep brain stimulation surgery and the widespread adaptation of implantation of the DBS system, lesioning procedures have taken a backseat. The long term effects of pallidal lesioning on motor and non-motor outcomes and the complications have not been systematically studied. Moreover the concerns of psychic akinesia and corticobulbar syndrome with bilateral pallidotomy has discouraged several practitioners from performing the procedure bilaterally. With the advent of non invasive therapies like MR guided focal ultrasound pallidotomy, the interest in radiofrequency pallidotomy is also resurfacing.

02

Conditions studied

  • Dystonia
  • Parkinson Disease
  • Essential Tremor
03

In context

Dystonia

213 studies on the registry are indexed under Dystonia; 54 are open to participants now.

This study's planned enrollment of 250 is above the median of 78 across 90 observational studies indexed under Dystonia.

Browse Dystonia studies →

Lead sponsor

All India Institute of Medical Sciences, New Delhi is the lead sponsor of 143 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with movement disorders such as Dystonia, Tremors or Parkinson's Disease who are being considered to undergo pallidal, subthalamic or thalamic lesioning procedures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with movement disorders admitted at the Neurology wards/attending clinics
  • Who are being considered for lesioning procedures
  • Of all ages and sexes

Exclusion criteria

Exclusion Criteria:

  • Those who deny consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Lesioning group

    Participants who undergo pallidal, subthalamic or thalamic lesioning for the management of Dystonia, Parkinson's disease or essential tremors

    Procedure: Pallidal, subthalamic or thalamic lesioning

  • Control group

    Participants who were considered for pallidal, subthalamic or thalamic lesioning for the management of Dystonia, Parkinson's disease or essential tremors but went on to continue best medical management

Interventions

  • ProcedurePallidal, subthalamic or thalamic lesioning

    Radiofrequency, ultrasound guided or other lesioning procedures of the Globus pallidus interna, subthalamic nucleus or Vim nucleus of the thalamus for the management of Movement disorders

06

What researchers measure

Primary outcomes

  1. Long term functional outcomes

    Long term outcomes in patients undergoing lesioning procedures for the treatment of Dystonia - Burke Fahn Marsden Dystonia - Disability scale. Lesser score is better

    Time frame: 1 year

  2. Long term functional outcomes

    Long term outcomes in patients undergoing lesioning procedures for the treatment of Parkinson Disease - Unified Parkinson Disease Rating Scale (UPDRS). Lesser score is better

    Time frame: 1 year

Secondary outcomes

  1. Predictors of outcomes

    To study the factors determining outcomes in patients undergoing lesioning procedures for movement disorders

    Time frame: 1 year

  2. Demography

    To study the demographic features (age, gender, age of onset, age at which lesioning is done) of patients undergoing lesioning procedures for the treatment of Movement disorders

    Time frame: Baseline at enrolment

  3. Clinical features

    To study the clinical features in patients undergoing lesioning procedures for the treatment of Movement disorders

    Time frame: Baseline at enrolment

  4. Laboratory findings

    To study the laboratory findings, genetic study results in patients undergoing lesioning procedures for the treatment of Movement disorders

    Time frame: Baseline at enrolment

  5. Imaging features

    To study the imaging features in patients undergoing lesioning procedures for the treatment of Movement disorders

    Time frame: Baseline at enrolment

  6. Treatment trends

    Treatment trends including medication prescription patterns, pattern of referral to surgery, need for redo surgery

    Time frame: At baseline

  7. Clinical features

    To study the clinical features in patients undergoing lesioning procedures for the treatment of Movement disorders

    Time frame: At 1 year

  8. Treatment trends

    Treatment trends including medication prescription patterns, pattern of referral to surgery, need for redo surgery

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

Time frame: From end of study to five years later

Access criteria: To be provided after approaching through Institute Ethics committee, AIIMS New Delhi

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Dec 2027, 44 months later.

Of 27 observational studies under Dystonia, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 58 and three quarters within 188. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Apr 8, 2024
StartEst.
Apr 15, 2024
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06352268
Responsible party
Arunmozhimaran Elavarasi (Assistant Professor, All India Institute of Medical Sciences, New Delhi) — Principal investigator
First posted
Apr 8, 2024
Start date
Apr 15, 2024 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 8, 2024

Study contacts

Arunmozhimaran Elavarasi, MD DM
Contact
arun_ela@yahoo.com
+919013844274
Manjari Tripathi, DM
Contact
mtripathiaiims@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion